JNJ-6358 is under clinical development by johnson & johnson and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JNJ-6358’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JNJ-6358 is under development for the treatment of solid tumors including clear cell, papillary renal carcinoma, epithelial ovarian primary peritoneal cancer and fallopian tube cancer, colorectal cancer, lung adenocarcinoma, endometrial cancer, and pancreatic cancer. It is a bi-specific antibody, acts by targeting CD3 and cells expressing human leukocyte antigen G (HLA-G). It is administered subcutaneously as a solution. The therapeutic candidate is developed based on Azymetric and Efect technology platforms.
Johnson & Johnson overview
johnson & johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; consumer products in oral care, baby care, beauty, over the counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, neurovascular care, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of JNJ-6358’s drug-specific PTSR and LoA scores, buy the report here.